Loading asset research
Neurogene Inc. Common Stock
NGNENasdaq · USD · StocksQuote as of · Exchange session not verified$35.48
-1.77%
Today
NGNE
Loading 1D prices…
Market cap
$710M
Volume
181.2K
52w high
$43.6652w low
$15.93Company profile
Neurogene Inc. Common Stock
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
131
Fiscal year end
1231
CIK
1404644
Session & valuation
Open$36.50
Previous close$36.12
Day high$37.64
Day low$35.38
30-day avg. volume206K
Outstanding shares20M
Diluted EPS-$4.24
Latest annual period
P/E (trailing)-8.37
P/E (forward)-6.85
Price / book2.59
Beta1.96
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ZVRAZevra Therapeutics Inc. Common Stock | $713.2M | $106.5M | +78.17% | $1.35 | -0.41% | Buy |
| GYREGyre Therapeutics Inc. Common Stock | $713.6M | $116.6M | +8.47% | $0.02 | -0.15% | Buy |
| COLLCollegium Pharmaceutical Inc. Common Stock | $705.2M | $780.6M | +8.07% | $1.73 | -0.83% | Buy |
| CTMXCytomX Therapeutics Inc. Common Stock | $716.9M | $76.2M | -22.79% | -$0.15 | -1.79% | Buy |
| CBIOCrescent Biopharma Inc. Common Stock | $721M | $10.8M | +1.42% | -$12.81 | -0.31% | Buy |